Can BMY's First CELMoD Approval Support Its Growth Strategy?
Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.
Zacks
Can Keytruda Sustain Merck's Growth in the Second Half of 2026?
MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.
Zacks
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.
Zacks
MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?
Merck's strong Keytruda sales and pipeline progress support its long-term outlook, but falling estimates and patent risks cloud the near term.
Zacks
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
Zacks
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
Zacks
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.
Zacks
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake
Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.
Zacks